# The Antioxidant and Skin-Brightening Effects of a Novel Caffeic Acid Derivative, Caffeic Acid-3,4-Dihydroxyphenylpropanolester

**Authors:** Kyu-lim Kim, Ju-hee Jeon, Yeonjoon Kim, Kyung-Min Lim

PMC · DOI: 10.3390/antiox14070806 · Antioxidants · 2025-06-29

## TL;DR

A new derivative of caffeic acid, CAD, was developed to improve skin brightening and antioxidant effects with better absorption than the original compound.

## Contribution

The novel lipophilic caffeic acid derivative CAD was synthesized and shown to have enhanced antioxidant and skin-brightening properties compared to caffeic acid.

## Key findings

- CAD exhibited stronger antioxidant activity than caffeic acid in DPPH and ABTS assays.
- CAD inhibited melanin production in B16F10 cells without cytotoxicity.
- CAD reduced intracellular ROS and suppressed tyrosinase activity and melanogenic pathways in skin models.

## Abstract

Caffeic acid (CA) is a naturally occurring polyphenol antioxidant found in coffee, tea, fruits, and vegetables, known for its strong antioxidant, anti-inflammatory, and anti-aging properties. However, its cosmetic application is limited because of poor dermal absorption due to its high polarity. This study aimed to evaluate the antioxidant and skin-brightening effects of a novel lipophilic CA derivative, CAD (caffeic acid-3,4-dihydroxyphenylpropanolester). CAD was synthesized by conjugating CA with 3,4-DHPEA, a lipophilic antioxidant derived from olive oil. In both DPPH and ABTS assays, CAD exhibited more potent antioxidant activity than CA. In B16F10 melanoma cells, CAD significantly inhibited melanin production without cytotoxicity at concentrations lower than those required for CA. Cellular assays using DCF-DA staining demonstrated that CAD effectively reduced intracellular ROS levels. Mechanistic studies revealed that CAD inhibited tyrosinase activity and downregulated the expression of TYR, TRP-1, and TRP-2. Additionally, CAD suppressed MITF phosphorylation, along with reduced phosphorylation of ERK and JNK, elucidating its anti-melanogenic mechanism. Importantly, CAD showed dose-dependent skin-brightening effects in the 3D human skin model Melanoderm™, as evidenced by increased lightness and histological evaluation. In conclusion, CAD demonstrates strong potential as a safe and effective antioxidant and skin-brightening agent for cosmetic applications.

## Linked entities

- **Genes:** TYR (tyrosinase) [NCBI Gene 7299], PRSS1 (serine protease 1) [NCBI Gene 5644], DCT (dopachrome tautomerase) [NCBI Gene 1638], MITF (melanocyte inducing transcription factor) [NCBI Gene 4286]
- **Chemicals:** caffeic acid (PubChem CID 689043), CAD (PubChem CID 3034811), 3,4-DHPEA (PubChem CID 82755), ABTS (PubChem CID 35688), DCF-DA (PubChem CID 104913)

## Full-text entities

- **Genes:** TRPC1 (transient receptor potential cation channel subfamily C member 1) [NCBI Gene 7220] {aka HTRP-1, TRP1}, ACOD1 (aconitate decarboxylase 1) [NCBI Gene 730249] {aka CAD, IRG1}, DCT (dopachrome tautomerase) [NCBI Gene 1638] {aka OCA8, TRP-2, TYRP2}, MITF (melanocyte inducing transcription factor) [NCBI Gene 4286] {aka CMM8, COMMAD, MI, MITF-A, WS2, WS2A}, TYR (tyrosinase) [NCBI Gene 7299] {aka ATN, CMM8, OCA1, OCA1A, OCAIA, SHEP3}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}
- **Diseases:** inflammatory (MESH:D007249), melanoma (MESH:D008545), cytotoxicity (MESH:D064420)
- **Chemicals:** 3,4-DHPEA (MESH:C005975), olive oil (MESH:D000069463), ABTS (MESH:C002502), CA (MESH:C040048), polyphenol (MESH:D059808), DPPH (MESH:C004931), melanin (MESH:D008543), DCF-DA (MESH:C029569), Caffeic Acid-3,4-Dihydroxyphenylpropanolester (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** B16F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12291847/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12291847/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12291847/full.md

---
Source: https://tomesphere.com/paper/PMC12291847